These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 22115327

  • 1. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [Abstract] [Full Text] [Related]

  • 2. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 4. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 5. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M, Joseph GJ, Princic N, Harrison DJ.
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A.
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW.
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [Abstract] [Full Text] [Related]

  • 12. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 15. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B, Fox KM, Watson C, Gandra SR.
    Adv Ther; 2012 Aug 01; 29(8):691-7. PubMed ID: 22903239
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
    Harley CR, Frytak JR, Tandon N.
    Am J Manag Care; 2003 Oct 01; 9(6 Suppl):S136-43. PubMed ID: 14577718
    [Abstract] [Full Text] [Related]

  • 20. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
    Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR.
    Adv Ther; 2014 Apr 01; 31(4):410-25. PubMed ID: 24604700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.